Type 2 diabetes (T2D) is a common disease affecting more than 100 million people in Western countries. It derives from the interaction between multiple genetic factors and environmental issues (mainly “lifestyle”). Being overweight or obese is the most well-known risk factor. T2D can be categorized as Metabolic Syndrome when it presents with obesity, hypertension, and dyslipidemia.
T2D-related hyperglycemia influences diffuse micro‐ and macro‐vascular damages causing chronic complications such as nephropathy, neuropathy, maculopathy, vasculopathy, and cardiovascular complications. All of these are associated with an increased risk of mortality. Unfortunately, previous studies have also demonstrated a correlation between T2D and the occurrence of some forms of cancer including breast, colorectal, lung and prostate.
Cancer, similar to T2D, is generally a multi-genic disease. The impact of T2D on the clinical and molecular heterogeneity of cancers (in both early and advanced stages) is largely unknown. The increasing availability of rapid and high-throughput genetic analyses (including DNA Next Generation Sequencing techniques) allows for the exploration of these complex genetic interactions.
This Research Topic will highlight the most recent advances in understanding the relationship between T2D and cancer in terms of clinical prognosis and molecular interactions. Particularly welcome are contributions focused on understanding the mechanisms underlying the T2D-related cancer risk and identifying common and innovative therapeutic pathways.
This Research Topic will include original articles as well as short research communications, review articles and opinions that are relevant to the treated issues. Articles consisting exclusively of bioinformatics or computational analyses of public databases will not be accepted.
Type 2 diabetes (T2D) is a common disease affecting more than 100 million people in Western countries. It derives from the interaction between multiple genetic factors and environmental issues (mainly “lifestyle”). Being overweight or obese is the most well-known risk factor. T2D can be categorized as Metabolic Syndrome when it presents with obesity, hypertension, and dyslipidemia.
T2D-related hyperglycemia influences diffuse micro‐ and macro‐vascular damages causing chronic complications such as nephropathy, neuropathy, maculopathy, vasculopathy, and cardiovascular complications. All of these are associated with an increased risk of mortality. Unfortunately, previous studies have also demonstrated a correlation between T2D and the occurrence of some forms of cancer including breast, colorectal, lung and prostate.
Cancer, similar to T2D, is generally a multi-genic disease. The impact of T2D on the clinical and molecular heterogeneity of cancers (in both early and advanced stages) is largely unknown. The increasing availability of rapid and high-throughput genetic analyses (including DNA Next Generation Sequencing techniques) allows for the exploration of these complex genetic interactions.
This Research Topic will highlight the most recent advances in understanding the relationship between T2D and cancer in terms of clinical prognosis and molecular interactions. Particularly welcome are contributions focused on understanding the mechanisms underlying the T2D-related cancer risk and identifying common and innovative therapeutic pathways.
This Research Topic will include original articles as well as short research communications, review articles and opinions that are relevant to the treated issues. Articles consisting exclusively of bioinformatics or computational analyses of public databases will not be accepted.